Publication:

Inclusion of CD80 in HSV Targets the Recombinant Virus to PD-L1 on DCs and Allows Productive Infection and Robust Immune Responses

Loading...
Thumbnail Image

Open/View Files

Date

2014

Journal Title

Journal ISSN

Volume Title

Publisher

Public Library of Science
The Harvard community has made this article openly available. Please share how this access benefits you.

Research Projects

Organizational Units

Journal Issue

Citation

Mott, Kevin R., Sariah J. Allen, Mandana Zandian, Omid Akbari, Pedram Hamrah, Hadi Maazi, Steven L. Wechsler, Arlene H. Sharpe, Gordon J. Freeman, and Homayon Ghiasi. 2014. “Inclusion of CD80 in HSV Targets the Recombinant Virus to PD-L1 on DCs and Allows Productive Infection and Robust Immune Responses.” PLoS ONE 9 (1): e87617. doi:10.1371/journal.pone.0087617. http://dx.doi.org/10.1371/journal.pone.0087617.

Abstract

CD80 plays a critical role in stimulation of T cells and subsequent control of infection. To investigate the effect of CD80 on HSV-1 infection, we constructed a recombinant HSV-1 virus that expresses two copies of the CD80 gene in place of the latency associated transcript (LAT). This mutant virus (HSV-CD80) expressed high levels of CD80 and had similar virus replication kinetics as control viruses in rabbit skin cells. In contrast to parental virus, this CD80 expressing recombinant virus replicated efficiently in immature dendritic cells (DCs). Additionally, the susceptibility of immature DCs to HSV-CD80 infection was mediated by CD80 binding to PD-L1 on DCs. This interaction also contributed to a significant increase in T cell activation. Taken together, these results suggest that inclusion of CD80 as a vaccine adjuvant may promote increased vaccine efficacy by enhancing the immune response directly and also indirectly by targeting to DC.

Description

Research Data

Keywords

Biology, Immunology, Immune Cells, Antigen-Presenting Cells, T Cells, Immune Response, Microbiology, Virology, Viral Vaccines, Medicine, Clinical Immunology, Immunity, Vaccination, Vaccine Development, Infectious Diseases

Terms of Use

This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service

Endorsement

Review

Supplemented By

Related Stories